[ad_1]
SYDNEY, March 25, 2019 / PRNewswire / – The Australian biotechnology company Kazia Therapeutics Ltd. (ASX: KZA, NASDAQ: KZIA), specializing in oncology, has been selected to present data from Cantrixil's Phase I study on Ovarian Cancer at the American Association for Cancer Research (AACR) 2019 Annual Meeting.
The annual meeting of AACR is one of the most prestigious academic conferences in the world and brings together about 20,000 representatives from universities, industry, governments and organizations advocacy around the world. The meeting will be held from March 29 to April 3 at the Georgia World Congress Center in Atlanta, Georgia, UNITED STATES.
Clinical Program Director, Daniel Berg will present on Phase I of Cantrixil of Kazia on ovarian cancer at the event April 1, 2019. Dr. Berg will present the data from Part A of the study – the dose escalation component – that completed the recruitment into October 2018.
TRX-E-002-1 (Cantrixil) is a third-generation benzopyran molecule, active against cancer stem cells. She is under development to treat ovarian cancer. It was developed in Australia and the first preclinical studies were conducted at Yale University. Cantrixil has been designated orphan for ovarian cancer by the FDA in the United States April 2015.
The summary presentation is entitled: Intraperitoneal TRX-E-002-1 Phase I study in patients with ovarian cancer, fallopian tube cancer, or cancer of the ovarian cancer Persistent or recurrent peritoneum: results of the phase of dose increase.
The summary was written by the principal investigators (PIs) of the trial, led by the two principal Australia and in the United States: Associate Professor Jermaine Coward at ICON Cancer Care at Brisbane, Queensland and Dr Don Dizon at the Lifespan Cancer Institute at Rhode Island Hospital. The trial is underway at six sites in the United States and the United Kingdom. Australia as following:
|
Country |
State |
Site |
Principal Investigator |
|
WE |
Rhode Island |
Life Cancer Institute, Providence |
Dr. Don Dizon |
|
WE |
Oklahoma |
Stephenson Cancer Center, Oklahoma City |
Assoc. Teacher. Kathleen Moore |
|
WE |
Texas |
Mary Crowley Cancer Research Center, Dallas |
Dr. Minal Barve |
|
Australia |
Queensland |
ICON Cancer Care, Brisbane |
Assoc. Teacher. Jermaine Coward |
|
Australia |
New South Wales |
Westmead Hospital, Sydney |
Pr Paul Harnett |
|
Australia |
South of Australia |
Flinders Medical Center, Adelaide |
Dr. Ganessan Kichenadbade |
"The key objective of Part A of the Phase I study was to evaluate the safety of the drug and to find the appropriate dose level to proceed to the next stage. We are excited to present our data to the AACR meeting looking forward to discussing our findings with clinicians and potential partners, "said Cantrixil Program Director Daniel Berg.
The details of the presentation session are as follows:
Title of the session: Phase I Clinical Trials: Part 3
Date and time: Monday, April 1, 2019 13:00 – 17:00
Location: Georgia World Congress Center, showroom B, poster section 16
Number of the display board: 15
Permanent summary number: CT091
Interested parties are encouraged to attend and can add the session to their itinerary here: https://www.abstractsonline.com/pp8/#!/6812/session/1315
In the meantime, the link to the summary is here: https://www.abstractsonline.com/pp8/#!/6812/presentation/9899
The content of the abstract and the presentation is embargoed until the beginning of the conference, where it will be available via the link above and on the Kazia website.
***ENDS***
For more information on Kazia Therapeutics or Cantrixil, visit: www.kaziatherapeutics.com
Logo – https://mma.prnewswire.com/media/766762/Kazia_Logo.jpg
SOURCE Kazia Therapeutics Ltd
Related Links
http://www.kaziatherapeutics.com
Source link
